Physician profile
Michael Gardner
NPI 1215993845
$1,407.80
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $231 · 2021: $407 · 2022: $458 · 2023: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $211.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $705.69 | 2019-2023 | Myrbetriq, Veozah |
| Abiomed | $137.93 | 2021 | |
| Antares Pharma, INC. | $122.91 | 2020-2022 | |
| 180 Medical, INC. | $47.93 | 2020-2022 | |
| Abbvie INC. | $45.53 | 2022 | |
| Clarus Therapeutics INC. | $42.13 | 2021 | |
| Halozyme INC | $39.03 | 2023 | |
| Pfizer INC. | $38.06 | 2022 | |
| Convatec INC. | $32.02 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $29.98 | 2023 | |
| Boston Scientific Corporation | $28.41 | 2020-2021 | |
| Myovant Sciences INC. | $26.50 | 2021 | |
| Rochester Medical Corporation | $22.19 | 2022 | |
| Myriad Genetic Laboratories, INC. | $18.56 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $17.39 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $15.64 | 2019-2022 | |
| Teleflex LLC | $13.90 | 2021 | |
| Urovant Sciences INC | $12.30 | 2021 | |
| Coloplast Corp | $11.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.